Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2018.8032

OL-0-0-8032

Articles

Curcumin may serve an anticancer role in human osteosarcoma cell line U-2 OS by targeting ITPR1

Luo

Zhanpeng

1 2 * Li

Dawei

1 2 * Luo

Xiaobo

2 Li

Litao

2 Gu

Suxi

2 Yu

Long

2 Ma

Yuanzheng

1 2

1Graduate School, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China 2Department of Orthopedics, The 309th Hospital of Chinese PLA, Beijing 100091, P.R. China

Correspondence to: Mr. Yuanzheng Ma, Department of Orthopedics, The 309th Hospital of Chinese PLA, 17 Heishanhu Road, Haidian, Beijing 100091, P.R. China, E-mail: mayuanzhengmy@hotmail.com *

Contributed equally

04 2018

13 02 2018

15 4 5593 5601 08042016 21062017

2018

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The present study aimed to determine the mechanisms of action of curcumin in osteosarcoma. Human osteosarcoma U-2 OS cells was purchased from the Cell Bank of the Chinese Academy of Sciences. RNA sequencing analysis was performed for 2 curcumin-treated samples and 2 control samples using Illumina deep sequencing technology. The differentially expressed genes were identified using Cufflink software. Enrichment and protein-protein interaction network analyses were performed separately using cluster Profiler package and Cytoscape software to identify key genes. Then, the mRNA levels of key genes were detected by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in U-2 OS cells. Finally, cell apoptosis, proliferation, migration and invasion arrays were performed. In total, 201 DEGs were identified in the curcumin-treated group. EEF1A1 (degree=88), ATF7IP, HIF1A, SMAD7, CLTC, MCM10, ITPR1, ADAM15, WWP2 and ATP5C1, which were enriched in ‘biological process’, exhibited higher degrees than other genes in the PPI network. RT-qPCR demonstrated that treatment with curcumin was able to significantly increase the levels of CLTC and ITPR1 mRNA in curcumin-treated cells compared with control. In addition, targeting ITPR1 with curcumin significantly promoted apoptosis and suppressed proliferation, migration and invasion. Targeting ITPR1 via curcumin may serve an anticancer role by mediating apoptosis, proliferation, migration and invasion in U-2 OS cells.

osteosarcoma curcumin RNA sequencing differentially expressed gene anticancer role

Introduction

Osteosarcoma is the most common primary bone malignancy in children and adolescents (1), which usually occurs in the metaphyseal region of tubular long bones (2). Although numerous modern therapies, including surgery, chemotherapy and radiotherapy have been used for treating osteosarcoma, the 5-year survival rate of patients with osteosarcoma is 60–70% (3). With the improvements in treatment techniques, the mortality rate of osteosarcoma is decreasing at ~1.3% per year (4). However, the etiology of osteosarcoma is unclear. Therefore, identification of the key genes associated with osteosarcoma is important for treatment of the disease.

As a type of plant polyphenol, curcumin is extracted from Curcuma longa (5) and exhibits anti-tumor, anti-inflammatory, antioxidant and anticoagulation capacities (6–9). Previous studies have demonstrated that curcumin serves functions in the progression of a number of types of cancer, including osteosarcoma (10), pancreatic cancer (11) and colon cancer (12). Fossey et al (13) revealed that FLLL32, a novel compound obtained from curcumin, inhibited signal transducers and activators of transcription 3 (STAT3) and induced apoptosis in osteosarcoma. Chang et al (14) indicated that curcumin induced apoptosis in the osteosarcoma MG63 cell line via mediating the reactive oxygen species/cytochrome c/caspase-3 pathway. Leow et al (15) demonstrated that curcumin and PKF118-310 may delay tumorigenesis and metastasis of osteosarcoma through inhibiting the Wnt/β-catenin signaling pathway. Taken together, these studies indicate that curcumin exhibits an effect on the pathogenesis of osteosarcoma through different pathways. Despite these aforementioned data, the target genes of curcumin in osteosarcoma remain unclear.

RNA sequencing (RNA-seq), which is based on deep-sequencing technology, is a more developed approach compared with transcriptome profiling (16). Several developments in RNA-seq, including mapping of the transcription start site, characterization of small RNA and detection of strand-specific, gene fusion and alternative splicing events, have been identified (17). In the present study, RNA-seq data analysis was performed on human osteosarcoma U-2 OS cells, which were treated by curcumin or dimethyl sulfoxide (DMSO). Differentially expressed genes (DEGs) between the curcumin-treated and control groups were identified, and the functions of the DEGs were predicted by functional and pathway enrichment analyses. A protein-protein interaction (PPI) network involving the DEGs was also constructed to additionally determine the target genes of curcumin in osteosarcoma. In addition, the mRNA levels of the top 10 nodes in the PPI network were confirmed, and it was identified that the mRNA levels of clathrin heavy chain (CLTC) and inositol 1,4,5-triphosphate receptor type 1 (ITPR1) in curcumin-treated cells were significantly increased. In addition, the effects of curcumin and ITPR1 on proliferation, apoptosis, migration and invasion in human osteosarcoma U-2 OS cells were investigated.

Materials and methods <sec> <title>Cell cultivation and curcumin treatment

The human osteosarcoma U-2 OS cell line was purchased from Cell Bank of Chinese Academy of Sciences (Shanghai, China). The U-2 OS cells were inoculated in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin-streptomycin (Gibco; Thermo Fisher Scientific, Inc.) and cultured at 37°C in a 5% CO₂ incubator (Thermo Fisher Scientific, Inc.). When the passaged cells reached 80–90% confluence, the cells were digested using pancreatin (Gibco; Thermo Fisher Scientific, Inc.). The digested cells were centrifuged at 1,000 × g and 4°C for 5 min, and then supernatant was discarded. Subsequently, the cells were preserved in frozen stock solution containing 10% DMSO (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), 40% FBS and 50% RPMI-1640 medium, and stored in program frozen box.

The U-2 OS cells were seeded in 6-well plates (2×10⁶ cell/well) and incubated in 5 ml serum-free medium in a 5% CO₂ incubator (Thermo Fisher Scientific, Inc.) at 37°C overnight. Curcumin (Sigma-Aldrich; Merck KGaA, 15 µmol/l) was dissolved in DMSO. Subsequently, U-2 OS cells were treated with 15 µM curcumin at 37°C in a 5% CO₂ incubator for 48 h (curcumin group). Concurrently, in the control groups, U-2 OS cells were treated with an equal volume of DMSO. Finally, the cells were washed twice with cold PBS.

All studies were approved by the Scientific and Ethical Committee of the 309th Hospital of Chinese People's Liberation Army (Beijing, China) and performed in accordance with the ethical standards.

RNA sequencing data

Total RNA was isolated from the U-2 OS cells using TRIzol^® (Takara Bio, Inc., Otsu, Japan) according to the manufacturer's protocol and quantified by spectrophotometry. Then, a transcriptome library was constructed using NEBNext^® Ultra™ RNA Library Prep kit for Illumina^® (cat. no. E7530; New England Biolabs, Inc., Ipswich, MA, USA) following the manufacturer's protocol. RNA was separated into RNA fragments (~200 nt), followed by double-stranded cDNA being synthesized and end-repaired. Then, adaptor ligation and polymerase chain reaction (PCR) enrichment (denaturation step: 98°C for 30 sec; 12 cycles: 98°C for 10 sec and annealing temperature 65°C for 75 sec; final extension step: 65°C for 5 min) were performed using the primers and reagents supplied with the NEBNext^® Ultra RNA Library Prep kit. The quality of the library was analyzed using Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA), and RNA was sequenced on Hiseq 2500 (Illumina, Inc., San Diego, CA, USA).

Data quality control and screening of DEGs

Subsequent to quality controls of the reads, they were mapped to the reference human genome (hg19) using TopHat (18) and assembled by Bowtie 1 software (19). Combined with sequence alignment results from TopHat and hg19 annotation information downloaded from the University of California, Santa Cruz (UCSC) database (https://www.astro.ucsc.edu/) (20), the DEGs between curcumin and control groups were identified using Cufflink software (21). P<0.01 and |log₂ fold change (FC)| ≥1 were set as cut-off criteria.

Functional and pathway enrichment analysis

Gene Ontology (GO, http://geneontology.org/) analysis develops a series of controlled and structured vocabularies for annotating functions of genes and their products (22). The Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.kegg.jp/) is a biological database, which stores genomic, chemical and systemic functional information (23). Using the cluster profiler (24) package in R, GO functional and KEGG pathway enrichment analyses were performed for upregulated and downregulated genes, respectively. The raw P-value was adjusted by the Benjamini-Hochberg method (25), and the adjusted P-value (also known as false discovery rate, FDR) <0.05 was used as a threshold.

Construction of PPI network

Human Protein Reference Database (HPRD) includes curated proteomic information and describes human PPIs (26). Using HPRD Release 9 (http://www.hprd.org/query) (26), pairs of interacting human proteins were downloaded, and the self-interacting protein pairs were removed. The DEGs were mapped with the downloaded PPI pairs, and those pairs involving the identified DEGs were extracted. Finally, the PPI network was visualized using Cytoscape software (version 2.8.0; www.cytoscape.org) and named as the DEG PPI network (27). Proteins are represented by nodes, the degree is the number of nodes which interact with the node in question, and the higher the degree the more important the protein in the PPI network.

Quantitative reverse transcription polymerase chain reaction (RT-qPCR) analysis

The cells treated with curcumin were dissolved in TRIzol^® reagent (Takara Bio, Inc.) for extraction of total RNA. Primers for key genes are summarized in Table I. Using SYBR^® Premix Ex Taq™ (Applied Biosystems; Thermo Fisher Scientific, Inc.), RT-qPCR amplification was performed according to the following thermocycling conditions: 50°C for 3 min, 95°C for 3 min, followed by 40 cycles of 95°C for 10 sec and 58°C for 30 sec. Gene expression was quantified and calculated by the comparative threshold (Cq) cycle method (2^−ΔΔCq) (28).

RNA interference assay

The cells in the siRNA group were digested by pancreatin at 37°C for 5 min, and then complete medium was added to neutralize the pancreatin. Subsequently, the cells were centrifuged at 1,000 × g for 5 min at 4°C, and the supernatant was discarded. Subsequent to being counted, the cells were seeded in 6-well plates (8×10⁵ cell/well) and cultured in 2 ml antibiotic-free complete medium in a 5% CO₂ incubator (Thermo Fisher Scientific, Inc.) at 3°C overnight. The ITPR1 small interfering (siRNA) were synthesized with the forward, 5′-AGACAGAAAACAGGAAAUUTT-3′ and reverse primer, (5′-AAUUUCCUGUUUUCUGUCUCA-3′). The ITPR1 siRNA (final concentration, 66 nM/l) and Lipofectamine^® 2000 reagent (1:25 vol/vol; Invitrogen; Thermo Fisher Scientific, Inc.) diluted with Opti-MEM medium (Gibco; Thermo Fisher Scientific, Inc.) were mixed and allowed to rest for 20 min. Subsequently, the cells were added to the siRNA mixture (500 µl/well) and Opti-MEM medium was replaced with complete medium following transfection for 6 h at room temperature. In addition, the cells were cultivated in a 5% CO₂ incubator (Thermo Fisher Scientific, Inc.) at 37°C for 48 h. The cells were then collected for RT-qPCR assay. The cells in the negative control group were treated with scrambled siRNA (final concentration, 66 nM/l) (Shanghai Biotend Biological Technology, Co., Ltd., Shanghai, China) as control and cultured like the cells in the siRNA group. The cells in the control group were treated without siRNA but otherwise culture the same as the cells in the siRNA group.

Cell proliferation assay

Subsequent to being digested and counted, the cells were seeded in a 96-well plate (4×10⁴ cell/well) and cultured in 100 ml antibiotic-free RPMI-1640 medium supplemented with 10% FBS (both FBS; Gibco; Thermo Fisher Scientific, Inc.) in a 5% CO₂ incubator (Thermo Fisher Scientific, Inc.) at 37°C overnight. Then, the cells were separately transfected at room temperature with the siRNA mixture, negative control siRNA and Lipofectamine 2000 reagent (Invitrogen; ThermoFisher Scientific Inc.) for 6 h. Subsequent to treatment with curcumin (Sigma-Aldrich; Merck KGaA), the cells were incubated with cell counting kit-8 at 37°C (CCK8; 10 µl/well; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) for 2 h. Finally, the absorption values under 450 nm were measured using an Epoch^™ Microplate Spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA) to calculate viability.

Flow cytometry

The U-2 OS cells were digested and counted, followed by seeding in a 6-well plate (8×10⁵ cell/well) and cultivation in 2 ml antibiotic-free RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc.) in a 5% CO₂ at 37°C overnight. Following transfection at room temperature for 6 h, the cells were treated with curcumin. The cells were digested by pancreatin, washed by PBS and resuspended in 1X binding buffer (BD Biosciences, San Jose, CA, USA). Subsequently, 100 µl of the above solution was transferred to flow cytometry tube, and stained with 5 µl fluorescein is isothiocyanate-Annexin V (BD Biosciences) and 5 µl propidium iodide (50 µg/ml; BD Biosciences) in the dark for 15 min at 25°C. Additionally, 400 µl 1X binding buffer (BD Biosciences) was added prior to flow cytometry using FCS Express 4 (De Novo Software, Glendale, CA).

Wound healing assay

Lines were drawn on the base of 6-well plate with an equal interval of ~0.5–1 cm. Then, the digested and counted cells were seeded in a 6-well plate (8×10⁵ cell/well) and cultured in 2 ml RPMI-1640 medium without serum (Gibco; Thermo Fisher Scientific, Inc.) in a 5% CO₂ at 37°C overnight. Then, the cells were separately transfected at room temperature with the siRNA mixture, negative control siRNA and Lipofectamine 2000 reagent (Invitrogen; Thermo Fisher Scientific Inc.) for 6 h. Afterwards, the cells were wound by drawing lines using a pipetting needle. After this, the cells were washed with PBS and then there were several channels on the surface of cultured cells. Subsequent to treatment with 15 µmol/l curcumin, images of movement of the cells were captured every 12 h and measured by Image-Pro Plus 6.0 software (Media Cybernetics Inc., Rockville, MD, USA).

Transwell assay

Subsequent to dilution with PBS (1:3 dilution), 50 µl Matrigel (1 mg/ml; Corning Incorporated, Corning, NY, USA) was solidified in a 24-well polycarbonate membrane following standing for 1 h at 37°C and resuspended following addition of 200 µl RPMI-1640 without serum (Gibco; Thermo Fisher Scientific, Inc.). The cells in each well of cell petri dish were added with 600 µl 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and then were cultured in a 6-well plate (8×10⁵ cell/well) in 2 ml RPMI-1640 medium with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) in 5% CO₂ at 37°C overnight. Following this, the transferred and treated cells were digested by pancreatin (Gibco: Thermo Fisher Scientific, Inc.) and cultivated in the upper wells (1×10⁵ cell/well) in a 5% CO₂ incubator (Thermo Fisher Scientific. Inc.) at 37°C for 12 h. Finally, the liquids in upper wells were discarded, and the cells that had not passed through the membranes were wiped off. The cells were stained with 0.1% crystal violet staining at room temperature for 20 min and observed under an inverted light microscope in 3 fields of view at magnification, ×200 (Olympus Corporation, Tokyo, Japan).

Statistical analysis

Using SPSS 12.0 software (SPSS Inc., Chicago, IL, USA), comparisons between groups were made using one-way ANOVA followed by a least significant difference test. All results are presented as the mean ± standard error. P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>Data quality control and analysis of DEGs

Quality control of the reads was performed and then assembled using Bowtie 1 software. The results are summarized in Table II. With P<0.01 and |log₂ FC| ≥1 as thresholds, the DEGs between the curcumin and control group were identified by Cufflink software. Compared with the control group, a total of 201 DEGs were identified in the curcumin-treated group, including 114 upregulated and 87 downregulated genes.

Functional and pathway enrichment analyses

The upregulated genes were significantly enriched in 3 GO terms, including ‘biological process’ (FDR=3.75×10⁻⁶), ‘cellular component organization’ (FDR=1.95×10⁻²) and ‘cellular component organization or biogenesis’ (FDR=2.08×10⁻²; Table III). The downregulated genes including hypoxia-inducible factor-1α (HIF1A) were significantly enriched in signal transduction (FDR=1.03×10⁻²), cell communication (FDR=1.89×10⁻²) and cellular process (FDR=5.62×10⁻³; Table III). In addition, there were no KEGG pathways significantly enriched for the upregulated or downregulated genes. Importantly, the GO term ‘biological process’ was enriched for upregulated genes [eukaryotic translation elongation factor 1α1 (EEF1A1), activating transcription factor 7 interacting protein (ATF7IP), SMAD family member 7 (SMAD7), CLTC, minichromosome maintenance 10 (MCM10), ITPR1, WW domain containing E3 ubiquitin protein ligase 2 (WWP2) and ATP synthase, H⁺ transporting, mitochondrial F1 complex, gamma polypeptide 1 (ATP5C1)], and downregulated genes [HIF1A and a disintegrin and metalloprotease 15 (ADAM15)].

Analysis of PPI network

A total of 39,240 PPI pairs were downloaded from HPRD Release 9. The DEG.PPI network had 929 interactions and 913 node genes, including 73 upregulated, 43 downregulated and 797 genes with no significant change in expression (Fig. 1). In particular, EEF1A1 (degree=88), ATF7IP (degree=64), HIF1A (degree=44), SMAD7 (degree=43), CLTC (degree=42), MCM10 (degree=28), ITPR1 (degree=27), ADAM15 (degree=24), WWP2 (degree=22) and ATP5C1 (degree=21) exhibited higher degrees in the DEG.PPI network.

Effects of curcumin treatment on the mRNA levels of EEF1A1, ATF7IP, HIF1A, SMAD7, CLTC, MCM10, ITPR1, ADAM15, WWP2 and ATP5C1 in U-2 OS cells

The mRNA levels of EEF1A1, ATF7IP, HIF1A, SMAD7, CLTC, MCM10, ITPR1, ADAM15, WWP2 and ATP5C1, which were the top 10 nodes with higher degrees in the PPI network, were measured. The results of RT-qPCR demonstrated that treatment with curcumin significantly increased the mRNA levels of CLTC and ITPR1 compared with DMSO-treated and control cells (P<0.01; Fig. 2). Additionally, the differential expression of ITPR1in curcumin-treated cells was more marked compared with CLTC.

RNA interference assay of ITPR1

With ITPR1 siRNA sequences, RNA interference assay was performed in U-2 OS cells. Then, the cells were collected for RT-qPCR analysis. The result of RT-qPCR demonstrated that ITPR1 was significantly decreased in cells transferred with ITPR1 siRNA sequences compared with the negative control cells and control cells (P<0.001; Fig. 3).

Effects of curcumin treatment and ITPR1 expression on proliferation in U-2 OS cells

The cell proliferation assay indicated that curcumin treatment was able to significantly suppress the proliferation of U-2 OS cells than the control group not treated with curcumin (P<0.05; Fig. 4), and the effect of curcumin-mediated suppression decreased subsequent to ITPR1 knockdown (P<0.01 vs. negative + curcumin; Fig. 4).

Effects of curcumin treatment and ITPR1 expression on apoptosis of U-2 OS cells

Flow cytometry was used to analysis the apoptotic rate of U-2 OS cells, and the results indicated that treatment with curcumin was able to significantly promote apoptosis of U-2 OS cells compared with the control not treated with curcumin (P<0.05; Fig. 5), while the apoptotic rate of U-2 OS cells transfected with ITPR1 siRNA sequences was significantly decreased (P<0.05; Fig. 5).

Effects of curcumin treatment and ITPR1 expression on migration of U-2 OS cells

A wound healing assay was performed to detect the migration of U-2 OS cells. The results indicated that treatment with curcumin significantly inhibited cell migration (P<0.01; Fig. 6). Compared with the control group, ITPR1 interference promoted migration of U-2 OS cells (P<0.01; Fig. 6). Meanwhile, ITPR1 interference significantly promoted migration of U-2 OS cells compared with curcumin-treated cells (P<0.05; Fig. 6).

Effects of curcumin treatment and ITPR1 expression on invasion of U-2 OS cells

Additionally, a Transwell assay was utilized to investigate the effects of curcumin treatment and ITPR1 expression on invasion of U-2 OS cells. The results of the Transwell assay suggested that treatment with curcumin was able to significantly inhibit invasion of U-2 OS cells compared with the control not treated with curcumin (P<0.05; Fig. 7). In addition, ITPR1 interference relieved the inhibitory effect of curcumin treatment on cell invasion (P<0.05; Fig. 7).

Discussion

In the present study, RNA-sequencing was used to perform transcriptomic analysis of human osteosarcoma U-2 OS cells treated with curcumin or DMSO. A total of 201 DEGs were identified in the curcumin-treated group, including 114 upregulated and 87 downregulated genes. Functional enrichment indicated that downregulated HIF1A was involved in biological processes, including signal transduction, cell communication and cellular process. HIF1A serves a key role in progression, invasion and metastasis of a number of types of human cancer, including osteosarcoma (29). It has been demonstrated that small hairpin RNA (shRNA)-mediated knockdown of HIF1A was able to efficiently inhibit the hypoxia transduction pathway and block the growth of osteosarcoma cells (30). HIF1A functions in osteosarcoma progression and the oxygen-dependent degradation of HIF1A may be critical for osteosarcoma (31). HIF1A is highly relevant to the primary occurrence or recurrence, size, clinical stage, pathological grade and angiogenesis of the osteosarcoma of the jaw, and may serve as a therapeutic target for the disease (32). Therefore, the present study hypothesized that HIF1A may also be involved in osteosarcoma.

EEF1A1 is overexpressed in methotrexate-treated osteosarcoma Saos-2 cell line, and may promote cell growth through the increase of protein translation (33). Concurrently, the inhibition of EEF1A1 may protect myotubes from apoptosis (34). Blanch et al (35) revealed that EEF1A1 exhibited effects on tumor protein (p) 53 and p73 through regulating human homologue of Mdm2 (HDM2) in a number of types of cancer, including osteosarcoma (35). Furthermore, several studies have demonstrated that the p53-family proteins participate in tumorigenesis via the mediation of the genes associated with cell cycle progression and apoptosis (36,37). In osteosarcoma Saos2 cells, SMAD7 may suppress bone morphogenetic protein 2 (BMP2)-induced differentiation and BMP/SMAD signaling through interacting with nuclear factor-κB (38). Previous studies have reported that SMAD7 overexpression may inhibit tumor progression and lung metastasis of osteosarcoma (39,40). Taken together, these data suggested that EEF1A1 and SMAD7 may participate in osteosarcoma. In the PPI network of the present study, EEF1A1 (degree=88), ATF7IP (degree=64), HIF1A (degree=44), SMAD7 (degree=43), CLTC (degree=42), MCM10 (degree=28), ITPR1 (degree=27), ADAM15 (degree=24), WWP2 (degree=22) and ATP5C1 (degree=21) exhibited the highest degrees. These genes were involved in the GO term ‘biological process’, indicating that they may be involved in the anticancer role of curcumin in human osteosarcoma U-2 OS cells through biological processes.

To additionally investigate the mechanisms of action of curcumin on human osteosarcoma U-2 OS cells, the mRNA levels of EEF1A1, ATF7IP, HIF1A, SMAD7, CLTC, MCM10, ITPR1, ADAM15, WWP2 and ATP5C1 in U-2 OS cells were analyzed. RT-qPCR demonstrated that treatment with curcumin significantly increased the mRNA levels of CLTC and ITPR1 in curcumin-treated cells, while the mRAN levels of ADAM15 dramatically decreased in curcumin-treated cells. Notably, the differential expression of ITPR1 was more significant compared with CLTC. Then, the effects of curcumin treatment and ITPR1 expression on proliferation, apoptosis, migration and invasion in U-2 OS cells were investigated. The results indicated that treatment with curcumin was able to significantly promote apoptosis and suppress proliferation, migration and invasion. It was also indicated that ITPR1 may contribute to the effects mediated by curcumin. A previous study had suggested that curcumin suppressed proliferation, invasion, survival, metastasis and angiogenesis of a number of types of cancer via interacting with cell signaling proteins including enzymes and inflammatory cytokines (41). Lee et al (42) with other previous studies demonstrated that treatment with curcumin promoted G1/S and G2/M cell cycle arrest and that activation of the caspase-3 signaling pathway induced apoptosis in human osteosarcoma cells (14,43). Li et al (44) indicated that curcumin inhibited proliferation of osteosarcoma via the inactivation of the Notch-1 signaling pathway. The ITPR1 gene encodes the intracellular calcium release channel type 1 InsP3R that can bind sensitized cells and cytochrome c to apoptotic stimuli (45–47). In osteoblastic cells, including G-292 osteosarcoma cells, exposure to interleukin-1β, tumor necrosis factor α and other apoptotic stimuli increase mRNA and protein levels of ITPR1 (48). These finding suggest that curcumin may serve an anticancer role in human osteosarcoma U-2 OS cells by regulating ITPR1.

In conclusion, a total of 201 DEGs were identified in the curcumin-treated group compared with the control group. Curcumin may serve an anticancer role by regulating apoptosis, proliferation, migration and invasion in human osteosarcoma U-2 OS cells. In addition, ITPR1 may be involved in the mechanism of action of curcumin treatment of osteosarcoma.

References 1

Broadhead

Clark

Myers

Dass

Choong

The molecular pathogenesis of osteosarcoma: A review

Sarcoma20119592482011

10.1155/2011/959248

21559216

Ottaviani

Jaffe

The epidemiology of osteosarcomaPediatric and adolescent osteosarcomaSpringer313 2010

Hao

Wang

Yang

Shao

Guo

Feng

Review of the molecular pathogenesis of osteosarcoma

Asian Pac J Cancer Prev15596759762014

10.7314/APJCP.2014.15.15.5967

25124559

Deng

Hua

Cai

Establishing an osteosarcoma associated protein-protein interaction network to explore the pathogenesis of osteosarcoma

Eur J Med Res18572013

10.1186/2047-783X-18-57

24330838

Chen

Liu

Chen

Fan

Han

Wang

Tan

Zhou

Cao

Zhou

Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers

Ann Pharmacother44103810452010

10.1345/aph.1M533

20484172

Rattigan

Maitra

Metabolomic profiling of curcumin effects on pancreatic cancer: Insights into anti-tumor activity

Pancreatology13e682013

10.1016/j.pan.2012.12.292

Motterlini

Foresti

Bassi

Green

Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress

Free Radic Biol Med28130313122000

10.1016/S0891-5849(00)00294-X

10889462

Chattopadhyay

Biswas

Bandyopadhyay

Banerjee

Turmeric and curcumin: Biological actions and medicinal applications

Curr Sci8744532004

Qiong

Ran

Pharmacological effects of curcumin and bladder cancer treatment research progress

Zhongyaoyao li yulinchuang30502012

Walters

Muff

Langsam

Born

Fuchs

Cytotoxic effects of curcumin on osteosarcoma cell lines

Invest New Drugs262892972008

10.1007/s10637-007-9099-7

18071634

Bao

Ali

Kong

Sarkar

Wang

Banerjee

Aboukameel

Padhye

Philip

Sarkar

Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer

PLoS One6e178502011

10.1371/journal.pone.0017850

21408027

Jaiswal

Marlow

Gupta

Narayan

Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells

Oncogene21841484272002

10.1038/sj.onc.1205947

12466962

Fossey

Bear

Lin

Schwartz

Fuchs

Fenger

Kisseberth

London

The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression and induces apoptosis in osteosarcoma cell lines

BMC Cancer111122011

10.1186/1471-2407-11-112

21443800

Chang

Xing

Curcumin induces osteosarcoma MG63 cells apoptosis via ROS/Cyto-C/Caspase-3 pathway

Tumour Biol357537582014

10.1007/s13277-013-1102-7

23959480

Leow

Tian

Ong

Yang

Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells

Invest New Drugs287667822010

10.1007/s10637-009-9311-z

19730790

Wang

Gerstein

Snyder

RNA-Seq: A revolutionary tool for transcriptomics

Nat Rev Genet1057632009

10.1038/nrg2484

19015660

Ozsolak

Milos

RNA sequencing: Advances, challenges and opportunities

Nat Rev Genet1287982011

10.1038/nrg2934

21191423

Trapnell

Pachter

Salzberg

TopHat: Discovering splice junctions with RNA-Seq

Bioinformatics25110511112009

10.1093/bioinformatics/btp120

19289445

Langmead

Aligning short sequencing reads with Bowtie

Curr Protoc BioinformaticsDec2010

10.1002/0471250953.bi1107s32

21154709

Fujita

Rhead

Zweig

Hinrichs

Karolchik

Cline

Goldman

Barber

Clawson

Coelho

The UCSC genome browser database: Update 2011

Nucleic Acids Res39Database IssueD876D8822010

20959295

Trapnell

Hendrickson

Sauvageau

Goff

Rinn

Pachter

Differential analysis of gene regulation at transcript resolution with RNA-seq

Nat Biotechnol3146532013

10.1038/nbt.2450

23222703

Gene Ontology Consortium: The gene ontology (GO) project in 2006

Nucleic Acids Res34Database IssueD322D3262006

16381878

Kanehisa

Araki

Goto

Hattori

Hirakawa

Itoh

Katayama

Kawashima

Okuda

Tokimatsu

Yamanishi

KEGG for linking genomes to life and the environment

Nucleic Acids Res36Database IssueD480D4842008

18077471

Wang

Han

clusterProfiler: An R package for comparing biological themes among gene clusters

OMICS162842872012

10.1089/omi.2011.0118

22455463

Benjamini

Hochberg

Controlling the false discovery rate: A practical and powerful approach to multiple testing

J R Stat Soc Series B Stat Methodol572893001995

Keshava Prasad

Goel

Kandasamy

Keerthikumar

Kumar

Mathivanan

Telikicherla

Raju

Shafreen

Venugopal

Human protein reference database-2009 update

Nucleic Acids Res37Database IssueD767D7722009

10.1093/nar/gkn892

18988627

Shannon

Markiel

Ozier

Baliga

Wang

Ramage

Amin

Schwikowski

Ideker

Cytoscape: A software environment for integrated models of biomolecular interaction networks

Genome Res13249825042003

10.1101/gr.1239303

14597658

Livak

Schmittgen

Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) method

Methods254024082001

10.1006/meth.2001.1262

11846609

Chau

Rogers

Aherne

Carroll

Collins

McDonald

Workman

Ashcroft

Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors

Cancer Res65491849282005

10.1158/0008-5472.CAN-04-4453

15930314

Yang

Wang

Therapeutic effects of RNA interference targeting HIF-1 alpha gene on human osteosarcoma

Zhonghua Yi Xue Za Zhi854094132005(In Chinese)

15854533

El Naggar

Clarkson

Zhang

Mathers

Tognon

Sorensen

Expression and stability of hypoxia inducible factor 1α in osteosarcoma

Pediatr Blood Cancer59121512222012

10.1002/pbc.24191

22544557

Chen

Feng

Expression and significance of hypoxemia-inducible factor-1alpha in osteosarcoma of the jaws

Oral Surg Oral Med Oral Pathol Oral Radiol Endod1062542572008

10.1016/j.tripleo.2008.01.029

18554951

Selga

Oleaga

Ramírez

de Almagro

Noé

Ciudad

Networking of differentially expressed genes in human cancer cells resistant to methotrexate

Genome Med1832009

10.1186/gm83

19732436

Ruest

Marcotte

Wang

Peptide elongation factor eEF1A-2/S1 expression in cultured differentiated myotubes and its protective effect against caspase-3-mediated apoptosis

J Biol Chem277541854252002

10.1074/jbc.M110685200

11724805

Blanch

Robinson

Watson

Cheng

Irwin

Eukaryotic translation elongation factor 1-alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivity

PLoS One8e664362013

10.1371/journal.pone.0066436

23799104

Kastan

Canman

Leonard

P53, cell cycle control and apoptosis: Implications for cancer

Cancer Metastasis Rev143151995

10.1007/BF00690207

7606818

Yang

Kaghad

Wang

Gillett

Fleming

Dötsch

Andrews

Caput

McKeon

p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities

Mol Cell23053161998

10.1016/S1097-2765(00)80275-0

9774969

Eliseev

Schwarz

Zuscik

O'Keefe

Drissi

Rosier

Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NFkappaB

Exp Cell Res31240502006

10.1016/j.yexcr.2005.09.016

16259979

Lamora

Talbot

Bougras

Amiaud

Leduc

Chesneau

Taurelle

Stresing

Le Deley

Heymann

Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma

Clin Cancer Res20509751122014

10.1158/1078-0432.CCR-13-3191

25107916

Won

Kim

Park

Expression of Smad and its signalling cascade in osteosarcoma

Pathology422422472010

10.3109/00313021003631288

20350217

Kunnumakkara

Anand

Aggarwal

Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins

Cancer Lett2691992252008

10.1016/j.canlet.2008.03.009

18479807

Lee

Kim

Curcumin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells

Anticancer Res29503950442009

20044614

Jin

Shen

Chen

Wang

Zhou

Apoptotic effects of curcumin on human osteosarcoma U2OS cells

Orhop Surg11441522009

10.1111/j.1757-7861.2009.00019.x

Zhang

Yin

Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of Notch-1 signaling

FEBS J279224722592012

10.1111/j.1742-4658.2012.08607.x

22521131

Wang

Vais

Thompson

Foskett

White

Apoptosis regulation by Bcl-x(L) modulation of mammalian inositol 1,4,5-trisphosphate receptor channel isoform gating

Proc Natl Acad Sci USA1041256512570

2007

10.1073/pnas.0702489104

17636122

Orrenius

Zhivotovsky

Nicotera

Regulation of cell death: The calcium-apoptosis link

Nat Rev Mol Cell Biol45525652003

10.1038/nrm1150

12838338

Boehning

Patterson

Snyder

Apoptosis and calcium: New roles for cytochrome c and inositol 1,4,5-trisphosphate

Cell Cycle32502522004

10.4161/cc.3.3.705

Bradford

Maglich

Kirkwood

IL-1 beta increases type 1 inositol trisphosphate receptor expression and IL-6 secretory capacity in osteoblastic cell cultures

Mol Cell Biol Res Commun373752000

10.1006/mcbr.2000.0194

10775502

Figure 1.

Protein-protein interaction network that involves the identified differentially expressed genes. Red and green nodes represent upregulated and downregulated genes, respectively. Blue nodes indicate the genes with no significant change in expression.

Figure 2.

Treatment with curcumin significantly increases the mRNA levels of CLTC and ITPR1 and decreases the mRNA levels of ADAM15 in curcumin-treated cells compared with dimethyl sulfoxide-treated and control cells, *P<0.01 compared with control cells, ^#P<0.01 compared with dimethyl sulfoxide-treated cells. EEF1A1, eukaryotic translation elongation factor 1α1; ATF7IP, activating transcription factor 7 interacting protein; HIF1A, hypoxia-inducible factor-1α; SMAD7, SMAD family member 7; CLTC, clathrin heavy chain; MCM10, minichromosome maintenance 10 replication initiation factor; ITPR1, inositol 1,4,5-triphosphate receptor type 1; ADAM15, a disintegrin and metalloprotease 15; WWP2, WW domain containing E3 ubiquitin protein ligase 2; ATP5C1, ATP synthase, H⁺ transporting, mitochondrial F1 complex, gamma polypeptide 1; Con, control; DMSO, dimethyl sulfoxide.

Figure 3.

ITPR1 is significantly decreased in cells transferred with ITPR1 siRNA sequences in comparison with negative control cells and control cells. ***P<0.001 when comparing the siRNA group with the negative control and control cells (compared separately). ITPR1, inositol 1,4,5-triphosphate receptor type 1; si, small interfering; con, control.

Figure 4.

Treatment with curcumin significantly suppresses proliferation of U-2 OS cells, and the effect of curcumin-mediated suppression decreases following knockdown of inositol 1,4,5-triphosphate receptor type 1. *P<0.05, compared with negative control cells and control cells; ^#P<0.01, compared with negative and curcumin-treated cells. si, small interfering; con, control.

Figure 5.

Treatment with curcumin significantly promotes apoptosis of U-2 OS cells, while the apoptotic rate of U-2 OS cells transfected with inositol 1,4,5-triphosphate receptor type 1 siRNA sequences were significantly decreased. *P<0.05, compared with negative control cells and control cells; ^#P<0.05, compared with negative and curcumin-treated cells. si, small interfering; con, control.

Figure 6.

Treatment with curcumin significantly inhibits cell migration, while ITPR1 interference promotes migration of U-2 OS cells (magnification, ×200). *P<0.01, compared with negative control cells and control cells (Note: for siRNA treated cells at 12 h, the *P<0.01 is compared with control cells); ^#P<0.05, compared with negative and curcumin-treated cells. si, small interfering; con, control. ITPR1, inositol 1,4,5-triphosphate receptor type 1.

Figure 7.

Treatment with curcumin significantly inhibits invasion of U-2 OS cells, and inositol 1,4,5-triphosphate receptor type 1 interference relieves the inhibitory effect of curcumin on cell invasion (magnification, ×200). *P<0.05 compared with negative control cells and control cells; ^#P<0.05 compared with negative and curcumin-treated cells. si, small interfering; con, control.

Table I.

Primer sequences for specific genes.

Name of primer	Primer sequences (5′-3′)
EEF1A1-hf	TGCCTGGGTCTTGGATAAAC
EEF1A1-hr	GCCTGAGATGTCCCTGTAAT
ATF7IP-hf	TTCCGCCCCAAAAGATTCAGA
ATF7IP-hr	CTGCTTCAAGTTGCTGACGATC
HIF1A-hf	ACTTCTGGATGCTGGTGATT
HIF1A-hr	GTTCAAACTGAGTTAATCCC
SMAD7-hf	ACCTTAGCCGACTCTGCGAACT
SMAD7-hr	TTTCAGCGGAGGAAGGCACA
CLTC-hf	TTGAATACGGTTGCTCTTGT
CLTC-hr	ATGCCAGTCAGAAGTAACCA
MCM10-hf	CTTTGAATACGGTTGCTCTT
MCM10-hr	GTACGGTAATTGATAATCTGG
ITPR1-hf	CCTGGTTGATGATCGTTGTGTT
ITPR1-hr	GCTTTTGGGCAGAGTAGCGGTT
ADAM15-hf	ATCCCTGCTGTGATTCTTTGACC
ADAM15-hr	TGGGCATAGGAGGCACAACG
WWP2-hf	CCCCGAATCCCAACACGACT
WWP2-hr	TCCCATCCAGCAGGCAGAGC
ATP5C1-hf	AAAAGCGAGGTTGCTACACT
ATP5C1-hr	ATGACTGACGCATCTCCAAA
GAPDH-hf	TGACAACTTTGGTATCGTGGAAGG
GAPDH-hr	AGGCAGGGATGATGTTCTGGAGAG

EEF1A1, eukaryotic translation elongation factor 1α1; ATF7IP, activating transcription factor 7 interacting protein; HIF1A, hypoxia-inducible factor-1α; SMAD7, SMAD family member 7; CLTC, clathrin heavy chain; MCM10, minichromosome maintenance 10 replication initiation factor; ITPR1, inositol 1,4,5-triphosphate receptor type 1; ADAM15, a disintegrin and metalloprotease domain 15; WWP2, WW domain containing E3 ubiquitin protein ligase 2; ATP5C1, ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1; h, human; f, forward; r, reverse.

Table II.

Results from quality control and assembly of sequencing data.

ID	Group	Number of cleaned paired-end reads	Number of aligned pair reads
14710C-1	Control	11,660,638	8,129,145
14710C-2	Control	12,351,701	8,531,536
14710C-5	Curcumin	13,820,514	8,368,710
14710C-6	Curcumin	11,927,581	8,797,461

Table III.

GO terms enriched for upregulated and downregulated genes.

Go term	Description	Gene number	FDR	Gene symbol
Upregulated DEGs
GO: 8150	Biological process	94	3.75×10-6	EEF1A1, ATF7IP, SMAD7, CLTC, MCM10
GO: 16043	Cellular component organization	41	1.95×10-2	ATF7IP, SMAD7, CLTC, CDH4, RTN3
GO: 71840	Cellular component organization or biogenesis	41	2.08×10-2	ATF7IP, SMAD7, CLTC, CDH4, RTN3
Downregulated DEGs
GO: 8150	Biological process	64	8.18×10-4	HIF1A, ADAM15, ARFRP1, AKAP9, ABI2
GO: 50896	Response to stimulus	40	5.62×10-3	HIF1A, ADAM15, ARFRP1, AKAP9, MALT1
GO: 51716	Cellular response to stimulus	34	5.62×10-3	HIF1A, ARFRP1, AKAP9, MALT1, MGLL
GO: 9987	Cellular process	59	5.62×10-3	HIF1A, ADAM15, ARFRP1,RBM5, PFDN6
GO: 7165	Signal transduction	29	1.03×10-2	HIF1A, ARFRP1, AKAP9, MALT1, RAP1GAP2
GO: 23052	Signaling	30	1.79×10-2	HIF1A, ARFRP1, AKAP9, MALT1, RAP1GAP2
GO: 44700	Single organism signaling	30	1.79×10-2	HIF1A, ARFRP1, AKAP9, MALT1, RAP1GAP2
GO: 7154	Cell communication	30	1.89×10-2	HIF1A, ARFRP1, AKAP9, MALT1, RAP1GAP2
GO: 71704	Organic substance metabolic process	46	1.89×10-2	HIF1A, ADAM15, ARFRP1,GSTO2, ADK
GO: 44238	Primary metabolic process	45	1.89×10-2	HIF1A, ADAM15, ARFRP1,GSTO2, ADK
GO: 50789	Regulation of biological process	43	2.04×10-2	HIF1A, ARFRP1, AKAP9, ABI2, RBM5
GO: 50794	Regulation of cellular process	41	2.55×10-2	HIF1A, ARFRP1, AKAP9, ABI2, RBM5
GO: 44699	Single-organism process	53	2.98×10-2	HIF1A, ADAM15, ARFRP1, AKAP9, ABI2
GO: 1568	Blood vessel development	6	4.65×10-2	HIF1A, ADAM15, ANKRD17, RAPGEF1, NPRL3, NRP1
GO: 43170	Macromolecule metabolic process	38	4.98×10-2	HIF1A, ADAM15, ABI2, RBM5, PFDN6

GO, Gene Ontology; DEGs, differentially expressed genes; FDR: false discovery rate; EEF1A1, eukaryotic translation elongation factor 1α1; ATF7IP, activating transcription factor 7 interacting protein; HIF1A, hypoxia-inducible factor-1α; SMAD7, SMAD family member 7; CLTC, clathrin heavy chain; MCM10, minichromosome maintenance 10 replication initiation factor; ITPR1, inositol 1,4,5-triphosphate receptor type 1; ADAM15, a disintegrin and metalloprotease domain 15; WWP2, WW domain containing E3 ubiquitin protein ligase 2; ATP5C1, ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1; RTN3, reticulon 3; GSTO2, glutathione S-transferase Omega 2; ADK, adenosine kinase; MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; RAP1GAP2, RAP1 GTPase activating protein 2; AKAP9, A-kinase anchoring protein 9; MGLL, monoglyceride lipase; PFDN6, prefoldin subunit 6; RBM5, RNA binding motif protein 5; ABI2, Abl interactor 2; NRP1, neuropilin 1; NPRL3, nitrogen permease regulator 3-like protein 3.